Upside – $REGN +6.9% (Q3 profit and revenue materially topped expectations) – $BTSG +6.4% (Q3 beat and full-year revenue and adjusted EBITDA guidance raised) – $MDLZ +6.4% (profit beat, volume-led growth and upbeat margin and 2027 commentary) – $RIVN +6.4% (Q3 beat and 2026 delivery outlook raised) – $AZN +5.9% (Q3 revenue and profit beat …
Read in context ›Takeda Pharmaceutical Company Stock (TAK)
Track Takeda Pharmaceutical Company stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
TAK
Takeda Pharmaceutical Company
healthcare
At close
$20.84
â–Ľ -0.09 (-0.43%)
Nov 11, 4:00 PM ET
After-hours
$21.25
â–˛ +0.41 (+1.97%)
Nov 11, 7:08 PM ET
Market Cap
$66.22B
P/E Ratio
27.4x
1Y Return
+52.66%
EPS (TTM)
$0.07
Read the latest TheStreet Pro articles mentioning Takeda Pharmaceutical Company, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
1 articleDaily Diary Mentions
1 mentionMondelez Up, Intel Down: Upside, Downside Movers in the Morning